Savara Inc. (SVRA)
Chart Events
Performance Outlook
| Previous Close | 1.5700 |
| Open | 1.5900 |
| Bid | 1.5400 x 800 |
| Ask | 1.5600 x 1300 |
| Day's Range | 1.5202 - 1.5900 |
| 52 Week Range | 1.0200 - 1.8200 |
| Volume | |
| Avg. Volume | 145,770 |
| Market Cap | 177.904M |
| Beta (5Y Monthly) | 1.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2690 |
| Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SVRA
Related Research
- Savara, Inc.Daily – Vickers Top Buyers & Sellers for 06/23/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat4 days agoArgus Research
- Zacks
Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?
Here is how Assertio (ASRT) and Savara Inc. (SVRA) have performed compared to their sector so far this year.
- Business Wire
Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic
AUSTIN, Texas, June 16, 2022--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced molgramostim has been awarded an Innovation Passport for the treatment of aPAP by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA). Innovation Passport is the entry point to the ILAP, a novel program aimed at accelerating the time to market and facilitating patient access to medicines in the UK.
- Simply Wall St.
Bullish insiders bet US$837k on Savara Inc. (NASDAQ:SVRA)
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
